Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company

Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024

Fineline Cube Mar 28, 2025

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...

Company

MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion

Fineline Cube Mar 28, 2025

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-1738 and HRS-5817 Clinical Trials

Fineline Cube Mar 28, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products...

Company

MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots

Fineline Cube Mar 28, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257...

Company Drug

Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation

Fineline Cube Mar 27, 2025

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from...

Company Deals Digital

Fangzhou Inc. Partners with Tencent Health to Advance AI-Driven Healthcare Solutions

Fineline Cube Mar 27, 2025

Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) has announced a strategic partnership with...

Company Drug

Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention

Fineline Cube Mar 27, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the European Commission (EC)...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials

Fineline Cube Mar 27, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Company Deals

Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933

Fineline Cube Mar 27, 2025

French pharmaceutical firm Servier has announced a global licensing agreement with US-based Black Diamond Therapeutics...

Company Deals Drug

Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization

Fineline Cube Mar 27, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...

Company Drug

Shanghai Junshi Biosciences’ Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma

Fineline Cube Mar 27, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval from...

Company Drug

Zhejiang Funow Medicine Launches Triple Cream for Melasma Treatment in China

Fineline Cube Mar 27, 2025

China-based Zhejiang Fonow Medicine Co., Ltd. (formerly known as: Zhejiang Rishengchang Pharmaceutical Co., Ltd.) has...

Company Drug

Luye Pharma’s BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer

Fineline Cube Mar 27, 2025

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...

Company Deals

Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI

Fineline Cube Mar 27, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot...

Company Deals

Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372

Fineline Cube Mar 27, 2025

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe...

Company Drug

AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment

Fineline Cube Mar 27, 2025

UK pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving another indication approval from China’s National...

Company Medical Device

Shanghai ZJ Bio-Tech’s HCV Nucleic Acid Test Kit Receives NMPA Approval

Fineline Cube Mar 27, 2025

China-based molecular diagnostic reagent specialist Shanghai Liferiver Bio-Tech Co., Ltd (SHA: 688317) has announced receiving...

Company Deals

Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources

Fineline Cube Mar 27, 2025

China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm...

Company Drug

Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia

Fineline Cube Mar 27, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) has announced its its subsidiaries Seacross Pharma...

Company Deals

Merck KGaA Partners with Roche to Commercialize Tepmetko in China

Fineline Cube Mar 26, 2025

Germany-based pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a partnership with Swiss giant...

Posts pagination

1 … 188 189 190 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.